Pharmaceutical Sales Employment for the United States
Do you have a need for Debt Consolidation, Debt Negotiation, or Debt Settlement? Obtain a FREE no-obligation debt reduction plan from CuraDebt.
IntellegoJobs – Current Job Opportunities, US Employment News, and Job Seeking Tips for the Bookkeeper, CPA, Programmer, Computer Hardware Engineer, Software Engineer, Computer Support Specialist, Systems Analyst, VoIP Engineer, Civil Engineer, Mechanical Engineer, High School Teacher, Middle School Teacher, Pharma Sales Rep, Sales Rep, Pharmacist, Physician Assistant, Physical Therapy Assistant, Registered Nurse, Pilot, and Truck Driver
Tweets by @intellegojobs
Welcome to our Pharmaceutical Sales Jobs site. The purpose of this site is to provide a frequently updated list of current employment opportunities for each state within the United States. Our lists come from RSS feeds provided by the most popular job search engines. If you are a pharma sales rep who is seeking employment, you should find this site useful.
It also should be noted that a professionally written resume will give you that competitive edge, which is needed in a tough job market. For a professionally written resume at a reasonable price, take a look here. This company is one of the leading resume writing services in the US according to the Washington Post, and is definitely worth a look.
Pharmaceutical Sales Jobs Listed by State – Updated Daily
The following data should be interesting to the pharmaceutical sales rep who resides within the United States. This data comes from the Bureau of Labor Statistics.
Employment Statistics for the Sales Representative – Technical and Scientific Products (Includes Pharmaceutical Products)
States with the highest concentration of sales reps (technical and scientific products) with annual salary:
(highest at top)
New Hampshire $77,120
South Dakota $63,310
Top paying states with annual salary:
(highest at top)
District of Columbia $85,050
Mean annual salary:
Metropolitan areas with the highest concentration of sales representatives (technical and scientific products) with annual salary:
Nashua, NH-MA NECTA Division $78,780
Framingham, MA NECTA Division $74,970
Lowell-Billerica-Chelmsford, MA-NH NECTA Division $99,010
San Jose-Sunnyvale-Santa Clara, CA $100,000
Lake County-Kenosha County, IL-WI Metropolitan Division $88,440
Top paying metropolitan areas:
Sacramento—Arden-Arcade—Roseville, CA $102,360
San Jose-Sunnyvale-Santa Clara, CA $100,000
Lowell-Billerica-Chelmsford, MA-NH NECTA Division $99,010
Bridgeport-Stamford-Norwalk, CT $98,520
Wenatchee, WA $98,100
Industries with the highest level of employment:
(highest at top)
Professional and Commercial Equipment and Supplies Merchant Wholesalers
Wholesale Electronic Markets and Agents and Brokers
Drugs and Druggists’ Sundries Merchant Wholesalers
Electrical and Electronic Goods Merchant Wholesalers
Computer Systems Design and Related Services
Top paying industries:
Satellite Telecommunications $107,050
Other Professional, Scientific, and Technical Services $102,100
Other Motor Vehicle Dealers $97,980
Other Telecommunications $92,770
Computer and Peripheral Equipment Manufacturing $91,080
Training and requirements needed:
Today, more frequently then not, employers are hiring sales representatives with a college degree, regardless of the type of product you are selling. If you want to be a pharmaceutical sales representative, indeed you should have a college degree. As a matter of fact, in most cases, you need a college degree if you want to sell any technical or scientific product.
The usual characteristics of any successful salesman such as a friendly personality, the ability to sell, and familiarity with the brand are also looked for in the pharmaceutical sales representative. Also, more so then many other sales positions, you need to sell the product to the physician within a very short period of time, usually a matter of minutes. This is simply because most doctors do not not have the time to listen to a long sales pitch.
In the pharmaceutical industry, it is essential that the sales rep have a complete and thorough knowledge of the drug he or she is selling. This includes side effects, interactions, efficacy, clinical trial data and more. Therefore extensive knowledge from the disciplines of chemistry and human biology are essential, along with a thirst for learning and understanding. Knowledge about drugs and medicines is also picked up from seminars and on the job training.
For more information about training required for the pharmaceutical sales representative in the United States go to Occupational Outlook Handbook provided by the Bureau of Labor Statistics.
Pharmaceutical Sales Jobs – Employment Growth and Outlook
Overall, sales employment growth in the United States is expected to be about average. Employment growth is expected to be around 9% between 2006 and 2016, which is average relative to all other occupations. It should be noted that this is for all sales positions.
As the elderly population in the United States continues to grow in size, their need for various medicines will also continue to grow. Drug companies will need to produce medicines with a high level of efficacy and fewer side effects in order to meet the medical needs of an increasing elderly population. Because the pharmaceutical sales representative is the interfacing pipeline between the drug company and the physician, this type of sales representative should continue to see increasing employment opportunities. Therefore, employment growth for the pharmaceutical sales representative should be greater then that which is expected for other sales positions.
It should also be noted that competition for technical and scientific product sales positions will be keen, including pharmaceutical sales representatives. This is because of the higher salary offered to individuals who hold these positions.
Vision Directed Interviews: How to Succeed within Interviews
You’ve probably read numerous job interview tips which list the ways to respond to the difficult interview questions: Tell me about Yourself; What are your work-related weaknesses?; Why are you leaving your current employer? These are the usual dreaded questions that we all expect to hear from interviewers. Typically interviewees are advised to create well-prepared and rehearsed scripts to respond to these dreaded questions. And so, during the course of the interview, interviewees sit on the edge of their seats waiting to respond, trying to remember the correct answers. And consequently, the interview becomes a race, a highly tense setting designed to stay one step ahead of the other with scripted conversation and pre-planned positioning and second-guessing. The possibility of authentically assessing the merits of the position and being able to evaluate how you might fit within the company’s culture and mission is minimized in this scenario. Go here to read this entire article
Pharmaceutical Industry News
Drugs.com - Pharma Industry News
Headline news from Drugs.com. Comprehensive and up-to-date drug news for both consumers and healthcare professionals.
Most-recognized brands, Oncology and Hematology, November 2013
The most-recognized oncology and hematology brand in North America is Epogen. The brand was most recognized by 4.9 percent of physicians in a survey conducted by Brand Institute Inc. during second-quarter 2013. Epogen, comprising...
Facts and Figures - November 2013
The average Medicare Part D patient filled 49 standardized 30-day prescriptions in 2010, according to research by the Dartmouth Atlas Project. At the high end, patients in Miami filled an average of 63 prescriptions, compared to...
Assessing future loss of exclusivity scenarios
By Mike Mabey and Gerard Loosschilder, Ph.D. The forecasting of scenario consequences helps brand teams contemplate “what if” situations regarding market possibilities and alternative courses of action. The discipline and...
To the Point - Technical difficulties
There is no doubt that our modern Internet and computing technology are confusing to those who really don’t know how the sausage is made, so to speak. It wasn’t so long ago that a member of Congress had talked about the...
The Last Word - How “The best thing that could ever happen to you” – happened to me
By Sander A. Flaum Our industry is tiny. As a result, I’ve had a chance to work with some of the best in the business – people responsible for developing life-enhancing and often life-extending drugs. People I’m proud to...
Glaxo and its transparency commitment
By Ed Silverman For the past year, GlaxoSmithKline has vowed to usher in a new era of transparency by creating a system to disclose detailed clinical trial data. This widely publicized move has been hailed by many critics of the...
Crossix POC Impact Delivers Campaign Measurement Accuracy
By Mia Burns (firstname.lastname@example.org) The point-of-care marketing channel includes physician offices where patients are primed to receive healthcare information. The POC marketing channel is growing fast, but traditional campaign...
Saint Luke's Heart Attack Survival Rates are Better than 98 Percent of Hospitals in the Nation
Saint Luke's Heart Attack Survival Rates are Better than 98 Percent of Hospitals in the Nation Latest data from CMS shows no hospital within 100 miles has a lower mortality rate KANSAS CITY, Mo., Dec. 5, 2013...
New Information on Defined Contribution Health Benefits Published
Zane Benefits Publishes New Information on Defined Contribution Health Benefits The Top Questions on Defined Contribution Health Benefits - Answered Park City, Utah (PRWEB) December 06, 2013 - Today, Zane Benefits, the number one...
Nearly Half of U.S. Adults Opted for Flu Vaccine
By Mia Burns (email@example.com) More than 104 million adults reported receiving the flu vaccine last year, indicating a nine percent increase year-over-year, according to Kantar Media’s MARS OTC/DTC Study. Despite this...
Nearly Half of U.S. Adults Opted for Flu Vaccine in 2012
By Mia Burns (firstname.lastname@example.org) More than 104 million adults reported receiving the flu vaccine in 2012, indicating a nine percent increase year-over-year, according to Kantar Media’s MARS OTC/DTC Study. Despite this increase,...
Biocartis and VIB Join Forces to Develop Unique Diagnostic Cancer Test
Biocartis and VIB Join Forces to Develop Unique Diagnostic Cancer Test LAUSANNE, Switzerland and MECHELEN, Belgium, December 6, 2013 /PRNewswire/ -- Today Biocartis and VIB announced their exclusive license agreement on a novel...
Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement
Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement for Promus PREMIER™ Stent System NATICK, Mass. and PARSIPPANY, N.J., Dec. 6, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) and...
EMA Starts In-Depth Review of Iclusig
Further review of Iclusig started LONDON, Dec. 6, 2013 - The European Medicines Agency has started an in-depth review of the benefits and risks of the leukaemia medicine Iclusig, particularly the risk of blood clots or blockages in...
GSK Launches Global Consortium
GSK launches global consortium with six renowned cancer research centres ■Oncology Clinical and Translational Consortium (OCTC) to include centres in US, Canada, France, the Netherlands and Spain ■Projects to focus on...
Novartis: Multiple Myeloma Drug Meets Phase III Endpoint
Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study Study of LBH589 plus bortezomib and dexamethasone met primary endpoint of extending PFS compared...
Celgene Rises As UBS Upgrades Shares to 'Buy'
NEW YORK (AP) — Shares of Celgene traded higher Thursday after a UBS analyst upgraded the biotechnology company, forecasting strong net income growth. THE SPARK: Analyst Matthew Roden raised his rating to "Buy" from "Neutral"...
By Christiane Truelove (email@example.com) Doctors love their smartphones, but do they love what pharma is providing them through mobile devices? The answer is mixed. The pharma industry is still struggling to find ways to be...
Report: VC Funding in Life Sciences Falls Behind
By Mia Burns (firstname.lastname@example.org) Although U.S. venture capital funding for the life science sector dropped by 15 percent in the third quarter of 2013, PricewaterhouseCoopers executives say that they are expecting investment within...
Ad-ventures in marketing VII
By Joshua Slatko email@example.com For the seventh time this past September, Med Ad News began once again its search for the future of pharmaceutical marketing. We sought out young companies, spin-offs, offerings, and ventures...
Arno Therapeutics Adds Steven Rubin, EVP of OPKO Health, Inc., as Board Observer
Arno Therapeutics Adds Steven Rubin, EVP of OPKO Health, Inc., as Board Observer Follows Recent OPKO Investment FLEMINGTON, N.J., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc....
INC Research Appoints Gregory M. Hockel, PhD to Lead Regulatory Consulting Practice
Provides global leadership for group guiding Company’s biopharmaceutical customers through regulatory approvals worldwide Raleigh, N.C., Nov. 18, 2013 – INC...
Melinta Therapeutics Appoints Sue Cammarata, M.D. as Chief Medical Officer
Melinta Therapeutics Prepares for Late-Stage Product Launches with Appointment of Sue Cammarata, M.D. as Chief Medical Officer NEW HAVEN, Conn, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment...
Repligen Appoints Biogen Idec Executive John G. Cox to Board of Directors
WALTHAM, Mass., Nov. 19, 2013 (GLOBE NEWSWIRE) -- Repligen Corporation today announced that it has elected to its Board of Directors John G. Cox, Executive Vice President of Pharmaceutical Operations & Technology for Biogen Idec...
Benchworks Promotes Thompson, Jamison
Benchworks is pleased to announce promotions for two of its staff members. Erika Thompson has been promoted to Account Executive, and Michelle Jamison will now hold the position of Senior Project Manager. In her new role, Erika...
Cho Named President of Harlan Korea
(Itingen, Switzerland; Nov. 26, 2013) — Kwan Goo Edmond (Ed) Cho, an industry veteran with a broad depth of experience in life sciences and pharmaceuticals, has been selected as the president of Harlan Korea. As president of...
Vision-Sciences Promotes Howard Zauberma
Vision-Sciences Promotes Howard Zauberman to Chief Executive Officer and President, and Appoints Him to Board of Directors ORANGEBURG, N.Y., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider...
Inventiv Health Hires Senior Life Sciences Executive to Oversee Expansion of Multi-Faceted Operations in India
Anita Tripathi Named President of inVentiv Health India BURLINGTON, Mass. – November 25, 2013 – inVentiv Health, offering best-in-class clinical, commercial and consulting services to the biopharmaceutical industry, has named...
Celerion Appoints John Horkulak as Executive Director, Eurasian Site Operations
(Lincoln, NE; Dec 05, 2013) – Celerion is pleased to announce the appointment of John Horkulak as Executive Director, Eurasian Site Operations. Mr. Horkulak will lead the efforts to further expand the company’s early phase...
Melinta Therapeutics Bolsters Executive Team with Appointment of Paul Estrem as Chief Financial Officer
NEW HAVEN, Conn, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today announced the appointment of Paul Estrem to the role of chief financial officer. Mr. Estrem brings more than 20 years of experience managing financial and...
Ventana Receives FDA Clearance
Ventana receives FDA clearance for Estrogen Receptor (ER) Image Analysis and Digital Read Application for breast cancer Companion Algorithm ER (SP1) image analysis software clearance completes the company's breast diagnostic...
Frost & Sullivan: Minimally Invasive Approach Boosts Demand for Endoscopy Devices in Australia, South Korea and Southeast Asia
Partnering with hospitals to provide infrastructure and guidance on endoscopy will help manufacturers strengthen the market SINGAPORE, Dec. 4, 2013 /PRNewswire/ -- Faster recovery times, better prognosis, and higher awareness...
Report: Approval of First Biosimilar Monoclonal Antibody In Europe Has Major Implications
The Approval Of The First Biosimilar Monoclonal Antibody In Europe Has Major Implications For 2014 And Beyond New Report from Decision Resources Identifies Key Clinical, Corporate and Regulatory Events Affecting the Biosimilars...
Novo Nordisk Study: Only 29% of Diabetics Say Doc Asks for Their Input
Only 29% of People With Diabetes Report That Their Doctors ask Them for Input for Their own Treatment Plans MELBOURNE, Australia, December 5, 2013 /PRNewswire/ -- Results from the global Diabetes Attitudes, Wishes and Needs 2...
Crossix POC Impact Increases Campaign Measurement Accuracy
First Patient-centric Point-of-Care (POC) Marketing Analytics Solution Significantly Increases Accuracy of Campaign Measurement Crossix Solutions’ exclusive patient-centered approach breaks the long-standing physician data...
Doctors Prefer Digital Media to In-Person Sales Reps
By Mia Burns (firstname.lastname@example.org) A new joint study from Capgemini Consulting and Quantia indicates that pharmaceutical companies’ shrinking access to physicians through traditional sales representatives is putting their in-office...
Chemocentryx Shares Edge Higher
Ahead of the Bell: Chemocentryx Shares Edge Higher Dec. 4, 2013 (AP)-Shares of ChemoCentryx Inc. advanced Wednesday before markets opened and a day after the drug developer said it was encouraged by initial results from a...
Arca Can Start Human Testing of Heart Drug Gencaro
WESTMINSTER, Colo., Dec. 4, 2013 (AP) — Federal regulators gave the go-ahead to Arca Biopharma to begin human clinical testing of its treatment for atrial fibrillation, the company said Wednesday. Arca believes it has identified...
Research Indicates that Physicians Prefer Digital Media
New Research from Capgemini Consulting and Quantia Reveals Digital Media is Now the Preferred Source by Physicians for Accessing Information from Pharmaceutical Companies Over Traditional In-Person Sales Representatives Study...
CereSpir Incorporated Appoints Richard Margolin, MD, as Vice President, Clinical Development
NEW YORK, Nov. 26, 2013 (GLOBE NEWSWIRE) -- CereSpir(TM) Incorporated, a company developing CHF 5074, a first-in-class microglial modulator, as a potential treatment for Alzheimer's disease, announced today Richard Margolin, MD,...
Human Resources Directory
List your business in premium web directories .
This website is listed under Job Search Directory
Powered by FirstRSS Plugin